keyword
MENU ▼
Read by QxMD icon Read
search

CNS Cancer

keyword
https://www.readbyqxmd.com/read/28941560/systematic-assessment-of-clinical-outcomes-and-toxicities-of-proton-radiotherapy-for-reirradiation
#1
REVIEW
Vivek Verma, Jean-Claude M Rwigema, Robert S Malyapa, William F Regine, Charles B Simone
Reirradiation (reRT) for locoregional recurrences poses unique challenges and risks; re-treatment using proton beam radiotherapy (PBT) could prove advantageous. Assessing clinical outcomes and toxicity profiles, this systematic review comprehensively evaluated available evidence regarding PBT reRT. Fourteen original investigations across central nervous system (CNS) (n=6), head/neck (H&N) (n=4), lung (n=2), and gastrointestinal (n=2) malignancies were analyzed. PBT for recurrent uveal melanoma achieved 5-year eye retention of 55%; for chordomas, reRT afforded a 2-year local control and overall survival (OS) of 85% and 80%, respectively...
September 20, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28940498/twice-weekly-pulse-and-daily-continuous-dose-erlotinib-as-initial-treatment-for-patients-with-epidermal-growth-factor-receptor-mutant-lung-cancers-and-brain-metastases
#2
Kathryn C Arbour, Mark G Kris, Gregory J Riely, Ai Ni, Kathryn Beal, Mariza Daras, Sara A Hayes, Robert J Young, Christopher R Rodriguez, Linda Ahn, William Pao, Helena A Yu
BACKGROUND: In a phase 1 study of pulse/continuous-dose erlotinib, no patient had disease progression in the central nervous system (CNS). This expansion cohort of the phase 1 study tested the same regimen in a cohort of individuals with epidermal growth factor receptor (EGFR)-mutant lung cancers with untreated brain metastases. METHODS: Patients had not received EGFR tyrosine kinase inhibitors or radiation for brain metastases. All received 1200 mg of erlotinib on days 1 and 2 and 50 mg on days 3 to 7 weekly...
September 21, 2017: Cancer
https://www.readbyqxmd.com/read/28933295/applications-of-multi-target-computer-aided-methodologies-in-molecular-design-of-cns-drugs
#3
Oleg A Raevsky, Azat Mukhametov, Veniamin Y Grigorev, Alexey Ustyugov, Shwu-Chen Tsay, Reuben Jih-Ru Hwu, Nagendra Sastry Yarla, George E Barreto, Gjumrakch Aliev, Sergey O Bachurin
: Discovery of drugs for diseases of the central nervous system (CNS) faces high attrition rates in clinical trials. Neural diseases are extremely complex in nature and typically associated with multiple drug targets. A conception of multi-target directed ligands (MTDL), widely applied to discovery of cancer pharmaceuticals, may be a perspective solution for CNS diseases. Special bio-informatics approaches have been developed which can assist the medicinal chemists in identification and structural optimization of MTDL...
September 20, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/28932368/cancer-risk-among-patients-with-multiple-sclerosis-a-cohort-study-in-isfahan-iran
#4
Masoud Etemadifar, Hamidreza Jahanbani-Ardakani, Sara Ghaffari, Maboobeh Fereidan-Esfahani, Hossein Changaei, Nazila Aghadoost, Ameneh Jahanbani Ardakani, Negin Moradkhani
BACKGROUND: Multiple sclerosis (MS), a central nervous system (CNS) autoimmune disorder, affects 2.3 million people around the world. Cancer kills around 7.5 million people annually. Both diseases have similar risks and intertwining molecular causes. Most studies focusing on MS and cancer have found an insignificant difference or reduction in the amount of cancer found in the MS community. METHODS: We performed a cohort study using data from Isfahan Multiple Sclerosis Society (IMSS) and Isfahan cancer society and followed-up for 8 years on average (2006-2014)...
2017: Caspian Journal of Internal Medicine
https://www.readbyqxmd.com/read/28924548/remodeling-the-blood-brain-barrier-microenvironment-by-natural-products-for-brain-tumor-therapy
#5
REVIEW
Xiao Zhao, Rujing Chen, Mei Liu, Jianfang Feng, Jun Chen, Kaili Hu
Brain tumor incidence shows an upward trend in recent years; brain tumors account for 5% of adult tumors, while in children, this figure has increased to 70%. Moreover, 20%-30% of malignant tumors will eventually metastasize into the brain. Both benign and malignant tumors can cause an increase in intracranial pressure and brain tissue compression, leading to central nervous system (CNS) damage which endangers the patients' lives. Despite the many approaches to treating brain tumors and the progress that has been made, only modest gains in survival time of brain tumor patients have been achieved...
September 2017: Acta Pharmaceutica Sinica. B
https://www.readbyqxmd.com/read/28922402/new-insights-into-the-metastatic-behavior-after-breast-cancer-surgery-according-to-well-established-clinicopathological-variables-and-molecular-subtypes
#6
Oreste Claudio Buonomo, Emanuele Caredda, Ilaria Portarena, Gianluca Vanni, Augusto Orlandi, Claudia Bagni, Giuseppe Petrella, Leonardo Palombi, Paolo Orsaria
Despite advances in treatment, up to 30% of patients with early breast cancer (BC) experience distant disease relapse. However, a comprehensive understanding of tumor spread and site-specific recurrence patterns remains lacking. This retrospective case-control study included 103 consecutive patients with metastatic BC admitted to our institution (2000-2013). Cases were matched according to age, tumor biology, and clinicopathological features to 221 patients with non-metastatic BC (control group). The median follow-up period among the 324 eligible patients was 7...
2017: PloS One
https://www.readbyqxmd.com/read/28919347/invasive-mold-infections-of-the-central-nervous-system-in-patients-with-hematologic-cancer-or-stem-cell-transplantation-2000-2016-uncommon-with-improved-survival-but-still-deadly-often
#7
Minas P Economides, Leomar Y Ballester, Vinodh A Kumar, Ying Jiang, Jeffrey Tarrand, Victor Prieto, Harrys A Torres, Dimitrios P Kontoyiannis
BACKGROUND: Historically considered to have very poor outcome, there is paucity of recent data regarding invasive mold infections (IMIs) of the central nervous system (CNS) in patients with hematologic cancer (HC) or stem cell transplantation (SCT). METHODS: We reviewed the records of HC patients and/or SCT recipients who were diagnosed with CNS IMIs (EORTC/MSG criteria) at MD Anderson Cancer Center (1/1/2000-6/31/2016). Risk factors for survival at day (d) 42 post diagnosis were assessed...
September 14, 2017: Journal of Infection
https://www.readbyqxmd.com/read/28919064/genetics-of-obesity-what-genetic-association-studies-have-taught-us-about-the-biology-of-obesity-and-its-complications
#8
REVIEW
Mark O Goodarzi
Genome-wide association studies (GWAS) for BMI, waist-to-hip ratio, and other adiposity traits have identified more than 300 single-nucleotide polymorphisms (SNPs). Although there is reason to hope that these discoveries will eventually lead to new preventive and therapeutic agents for obesity, this will take time because such developments require detailed mechanistic understanding of how an SNP influences phenotype (and this information is largely unavailable). Fortunately, absence of functional information has not prevented GWAS findings from providing insights into the biology of obesity...
September 14, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28917942/in-vivo-and-in-vitro-testing-of-native-%C3%AE-conotoxins-from-the-injected-venom-of-conus-purpurascens
#9
REVIEW
Mickelene F Hoggard, Alena M Rodriguez, Herminsul Cano, Evan Clark, Han-Shen Tae, David J Adams, Tanja A Godenschwege, Frank Marí
α-Conotoxins inhibit nicotinic acetylcholine receptors (nAChRs) and are used as probes to study cholinergic pathways in vertebrates. Model organisms, such as Drosophila melanogaster, express nAChRs in their CNS that are suitable to investigate the neuropharmacology of α-conotoxins in vivo. Here we report the paired nanoinjection of native α-conotoxin PIA and two novel α-conotoxins, PIC and PIC[O7], from the injected venom of Conus purpurascens and electrophysiological recordings of their effects on the giant fiber system (GFS) of D...
September 13, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/28916530/elucidation-of-the-impact-of-p-glycoprotein-and-breast-cancer-resistance-protein-on-the-brain-distribution-of-catechol-o-methyltransferase-inhibitors
#10
Joana Bicker, Ana Fortuna, Gilberto Alves, Patricio Soares-da-Silva, Amilcar Falcao
P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) are clinically important efflux transporters that act cooperatively at the blood-brain barrier, limiting the entry of several drugs into the CNS and affecting their pharmacokinetics, therapeutic efficacy and safety. In the present study, the interactions of catechol-O-methyltransferase (COMT) inhibitors (BIA 9-1059, BIA 9-1079, entacapone, nebicapone, opicapone and tolcapone) with P-gp and BCRP were investigated in order to determine the contribution of these transporters in their access to the brain...
September 15, 2017: Drug Metabolism and Disposition: the Biological Fate of Chemicals
https://www.readbyqxmd.com/read/28913566/adar-rna-editing-in-human-disease-more-to-it-than-meets-the-i
#11
REVIEW
Angela Gallo, Dragana Vukic, David Michalík, Mary A O'Connell, Liam P Keegan
We review the structures and functions of ADARs and their involvements in human diseases. ADAR1 is widely expressed, particularly in the myeloid component of the blood system, and plays a prominent role in promiscuous editing of long dsRNA. Missense mutations that change ADAR1 residues and reduce RNA editing activity cause Aicardi-Goutières Syndrome, a childhood encephalitis and interferonopathy that mimics viral infection and resembles an extreme form of Systemic Lupus Erythmatosus (SLE). In Adar1 mouse mutant models aberrant interferon expression is prevented by eliminating interferon activation signaling from cytoplasmic dsRNA sensors, indicating that unedited cytoplasmic dsRNA drives the immune induction...
September 14, 2017: Human Genetics
https://www.readbyqxmd.com/read/28905151/the-role-of-the-neural-niche-in-brain-metastasis
#12
REVIEW
Reid Hoshide, Rahul Jandial
Cancers with neurologic metastasis are a burdensome affliction. As primary cancer care improves, the incidence of metastatic cancer increases as a result of prolonged survival time. Because of this, advances in the understanding of the mechanisms of metastasis are important for the development of continuing management strategies. Knowing how metastatic tumor cells engage, survive, and proliferate in the central nervous system (CNS) is an important first step in developing treatment paradigms. The neural niche is the soil of the CNS that accommodates tumor cells, is a microenvironment of cell signaling that exists between the tumor cell and the native neural cellular network...
September 13, 2017: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/28903085/multiscale-molecular-dynamics-simulations-of-lipid-interactions-with-p-glycoprotein-in-a-complex-membrane
#13
Laura Domicevica, Heidi Koldsø, Philip C Biggin
P-glycoprotein (P-gp) can transport a wide range of very different hydrophobic organic molecules across the membrane. Its ability to extrude molecules from the cell creates delivery problems for drugs that target proteins in the central nervous system (CNS) and also causes drug-resistance in many forms of cancer. Whether a drug will be susceptible to export by P-gp is difficult to predict and currently this is usually assessed with empirical and/or animal models. Thus, there is a need to better understand how P-gp works at the molecular level in order to fulfil the 3Rs: Refinement, reduction and replacement of animals in research...
September 2, 2017: Journal of Molecular Graphics & Modelling
https://www.readbyqxmd.com/read/28900876/improving-diagnostic-and-therapeutic-outcomes-in-pediatric-brain-tumors
#14
REVIEW
Sydney T Grob, Jean M Mulcahy Levy
Pediatric brain tumors are the primary cause of cancer-related death during childhood. Unfortunately, the number of primary and metastatic brain tumors is steadily increasing while the mortality rates for many central nervous system (CNS) lesions have remained stagnant. Molecularly defined tumor classes have been added to the most recent 2016 World Health Organization (WHO) Classification System of Central Nervous System Brain Tumors, driving potential new treatments and identifying targets to improve survival for these patients...
September 12, 2017: Molecular Diagnosis & Therapy
https://www.readbyqxmd.com/read/28890157/the-cumulative-burden-of-surviving-childhood-cancer-an-initial-report-from-the-st-jude-lifetime-cohort-study-sjlife
#15
Nickhill Bhakta, Qi Liu, Kirsten K Ness, Malek Baassiri, Hesham Eissa, Frederick Yeo, Wassim Chemaitilly, Matthew J Ehrhardt, Johnnie Bass, Michael W Bishop, Kyla Shelton, Lu Lu, Sujuan Huang, Zhenghong Li, Eric Caron, Jennifer Lanctot, Carrie Howell, Timothy Folse, Vijaya Joshi, Daniel M Green, Daniel A Mulrooney, Gregory T Armstrong, Kevin R Krull, Tara M Brinkman, Raja B Khan, Deo K Srivastava, Melissa M Hudson, Yutaka Yasui, Leslie L Robison
BACKGROUND: Survivors of childhood cancer develop early and severe chronic health conditions (CHCs). A quantitative landscape of morbidity of survivors, however, has not been described. We aimed to describe the cumulative burden of curative cancer therapy in a clinically assessed ageing population of long-term survivors of childhood cancer. METHODS: The St Jude Lifetime Cohort Study (SJLIFE) retrospectively collected data on CHCs in all patients treated for childhood cancer at the St Jude Children's Research Hospital who survived 10 years or longer from initial diagnosis and were 18 years or older as of June 30, 2015...
September 7, 2017: Lancet
https://www.readbyqxmd.com/read/28887756/development-of-the-pediatric-neuro-oncology-rating-of-treatment-intensity-pnorti
#16
Matthew C Hocking, Wendy Hobbie, Michael J Fisher
Measures of treatment intensity for childhood cancer are needed in research in order to control for variability in treatments. Existing measures of treatment intensity for childhood cancers do not reflect the complexities of treatment protocols for central nervous system (CNS) tumors. This paper describes the development of the Pediatric Neuro-Oncology Rating of Treatment Intensity (PNORTI). PNORTI development occurred in three phases. Phase 1: five experts in pediatric neuro-oncology created a 5-point scale of treatment intensity and 42 pediatric neuro-oncology providers completed a three-part online questionnaire to evaluate the classification system and apply the rating system to 16 sample patients...
September 8, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28882584/prophylactic-cranial-irradiation-pci-vs-active-mri-surveillance-for-small-cell-lung-cancer-the-case-for-equipoise
#17
REVIEW
Chad G Rusthoven, Brian D Kavanagh
Prophylactic cranial irradiation (PCI) for small-cell lung cancer (SCLC) offers a consistent reduction in the incidence of brain metastases (BM), at the cost of measurable toxicity to neurocognitive function and quality of life in the setting of characteristic pathologic changes to the brain. The sequelae of PCI have historically been justified by the perception of an overall survival (OS) advantage specific to SCLC. This rationale has now been challenged by a randomized trial in extensive-stage SCLC demonstrating equivalent progression-free survival and a trend toward improved OS with PCI omission in the context of modern MRI staging, surveillance, and salvage therapy...
September 4, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28881501/drug-drug-interaction-potential-in-men-treated-with-enzalutamide-mind-the-gap
#18
G E Benoist, I M van Oort, S Smeenk, A Javad, D M Somford, D M Burger, N Mehra, N P van Erp
AIM: Metastatic castration resistant prostate cancer (mCRPC) patients are generally older patients with several co-morbidities and are therefore more at risk for complications due to drug-drug interactions(DDIs). We assessed the prevalence of potential DDIs in a cohort of mCRPC patients treated with enzalutamide. METHODS: We conducted a retrospective review of pharmacy records to retrieve individual drug histories of mCRPC patients who started enzalutamide therapy in a tertiary care setting...
September 7, 2017: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28875834/argemone-mexicana-a-boon-to-medicinal-and-pharmacological-approaches-in-current-scenario
#19
A Nancy, A Praveena
Nature is God's gift to human beings. Natural products are a source of new chemical diversity and are the choice of today's world. Nature itself gives remedy to all our health problems. The sources of natural product are plants, animals and microorganisms. Among them plant and its products are more reliable for its renewability and therefore, considered as fortunate thing for human welfare. Our traditional system of medicine which has been followed by our ancestors has its own impact on human life. Due to the inadequate knowledge many plant derived products (drugs) has not yet been explored to the society...
August 30, 2017: Cardiovascular & Hematological Agents in Medicinal Chemistry
https://www.readbyqxmd.com/read/28871264/neuroinflammation-bone-marrow-stem-cells-and-chronic-pain
#20
REVIEW
Yul Huh, Ru-Rong Ji, Gang Chen
Current treatments for chronic pain, such as inflammatory pain, neuropathic pain, and cancer pain are insufficient and cause severe side effects. Mounting evidence suggests that neuroinflammation in the peripheral and central nervous system (PNS and CNS) plays a pivotal role in the genesis and maintenance of chronic pain. Characteristic features of neuroinflammation in chronic pain conditions include infiltration of immune cells into the PNS [e.g., the sciatic nerve and dorsal root ganglion (DRG)], activation of glial cells such as microglia and astrocytes in the CNS (spinal cord and brain), and production and secretion of pro-inflammatory cytokines and chemokines [TNF, interleukin (IL)-1β, IL-6, CCL2, and CXCL1]...
2017: Frontiers in Immunology
keyword
keyword
14978
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"